The NPPA has set ceiling prices for 355 drugs, 882 formulations: Mandaviya

The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for 355 drugs and 882 formulations as part of the 2015 national essential drugs list, Parliament informed on Tuesday.

“Most of the drugs that are part of the COVID-19 management protocol have ceiling prices, namely paracetamol, dexamethasone, methylprednisolone, IVIG, enoxaparin, budesonide, heparin and amphotericin, etc, “Chemicals and Fertilizers Minister Mansukh Mandaviya said in a statement. written answer to a question in the Lok Sabha.

In the case of a few unscheduled drugs like remdesivir, which are part of the COVID-19 protocol and are unscheduled, upon government intervention, the MRPs of various brands of remdesivir have been voluntarily reduced by major manufacturers / marketers of the drug. injection of remdesivir. (freeze-dried), he added.

Maximum inter-brand retail prices (MRP) which ranged up to Rs 5,400 per vial have been reduced to less than Rs 3,500, the minister said.

In addition, to facilitate availability and ensure an affordable price, the NPPA capped the profit margin for oxygen concentrators at 70% on the distributor-level price video notification dated June 3, 2021 and on the oximeter. monitor, glucometer, blood pressure monitor, nebulizer and digital thermometer. video notification dated July 13, 2021, “he added.

In addition, the retail prices of 1,640 formulations have been set under the DPCO, 2013, to date and in recent years, exercising extraordinary powers under the DPCO, 2013, in the public interest. The NPPA had set the ceiling price for stents in February 2017, the ceiling price for knee implants in August 2017, and also capped the profit margin on a selection of 42 cancer drugs in February 2019, Mandaviya said.

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

Source link

Comments are closed.